UK Court Favors Novartis In Lucentis Patent Suit

Law360, New York (July 6, 2011, 5:54 PM EDT) -- A U.K. judge ruled Tuesday that Novartis Pharmaceuticals U.K. Ltd.'s vision-loss drug Lucentis does not infringe two patents held by AstraZeneca PLC unit MedImmune Ltd.

Judge Richard Arnold of the High Court of Justice ruled that not only did Lucentis not infringe the two MedImmune patents, both were invalid as obvious in view of prior art.

Lucentis is used to treat age-related macular degeneration, which can lead to vision loss. MedImmune sued Novartis in the U.K. in December 2009, alleging infringement of patents for a screening...
To view the full article, register now.